June 28, 2005 Expressing concern about “psychiatric risks”, the U.S. Food and Drug Administration (FDA) intends to change the warnings for drugs used to treat Attention Deficit Hyperactivity Disorder (ADHD). The drugs they refer to are amphetamine-like, Schedule II products: Concerta, Ritalin, Adderall (an amphetamine banned in Canada but not the US) and Strattera. The psychiatric side effects mentioned in the FDA’s release, “FDA: Concerned With Psychiatric Risks With ADHD Drugs,” are “visual hallucinations, suicidal ideation, psychotic behavior, as well as aggression or violent behav ...   read more